

Accepted Manuscript: Authors' Copy

The role of the metabotropic glutamate receptor 5 in nicotine addiction

Running head: mGluR5 and nicotine addiction

Authors: Funda Akkus^{1,4}, Sylvia Terbeck⁵, Connor. J. Haggarty⁵, Valerie Treyer², Janan Janine Dietrich³, Stefanie Hornschuh³, and Gregor Hasler¹

1. Department of Psychiatry, University of Fribourg, Fribourg, Switzerland
2. Department of Nuclear Medicine, University Hospital Zurich,, Switzerland
3. Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg
4. Psychiatrie St. Gallen Nord, Wil, Switzerland
5. School of Psychology, Liverpool John Moors University, United Kingdom

Key words: Nicotine, addiction, relapse, mGluR5

Disclosure information: Funda Akkus, Sylvia Terbeck, Connor. Haggarty, Valerie Treyer, Janan Janine Dietrich, Stefanie Hornschuh, and Gregor Hasler report no conflicts of interest affecting this publication.

Corresponding author: Funda Akkus; Email: funda.akkus@unifr.ch

Abstract

This review summarizes the evidence for the potential involvement of metabotropic glutamate receptor 5 (mGluR5) in the development of nicotine addiction. Nicotine is consumed worldwide and is highly addictive. Previous research has extensively investigated the role of dopamine in association with reward learning and addiction, which has provided strong evidence for the involvement of dopaminergic neuronal circuitry in nicotine addiction. More recently, researchers focused on glutamatergic transmission after nicotine abuse, and its involvement in the reinforcing and rewarding effects of nicotine addiction. A number of

DOI: 10.1017/S1092852920001704

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article may be cited using its DOI.

robust preclinical and clinical studies have shown mGluR5 signaling as a facilitating mechanism of nicotine addiction and nicotine withdrawal. Specifically, clinical studies have illustrated lower cortical mGluR5 density in smokers compared to non-smokers in the human brain. In addition, mGluR5 might selectively regulate craving and withdrawal. This suggests that mGluR5 could be a key receptor in the development of nicotine addiction and therefore clinical trials to examine the therapeutic potential of mGluR5 agents could help to contribute to reduce nicotine addiction in society.

Abbreviations: mGluR5 - metabotropic glutamate receptor 5, mGluR - metabotropic glutamate receptor, iGluR – ionotropic glutamate receptor, DA – Dopamine, NAc – Nucleus Accumbens.

Epidemiology of Nicotine Addiction

Nicotine addiction is one of the most common and preventable chronic psychiatric conditions characterised by the compulsion to seek and use nicotine¹. Worldwide, there are approximately 1.1 billion adult smokers and 80 % of them live in low- and middle- income countries². More than 7 million smokers die each year because of smoking related diseases, around 890,000 of which are being exposed to second-hand smoke (i.e. indirect exposure to smoke exhaled by smokers)³. Stopping nicotine consumption can lead to significant withdrawal symptoms for instance, depressed mood, attention/concentration problems, anhedonia, cravings, dysphoria, anxiety, irritability, and somatic problems (such as insomnia and weight gain)^{1,4}. In the USA, about 40 – 50 % of smokers try to stop smoking every year, however, only about 6 % are able abstain for at least 6 to 12 months⁵. The majority of relapses happen within the first week of abstinence, with 15 – 28 % of smokers staying abstinent for 1 month, 10 - 20% remaining abstinent 3 months, and 3 – 5 % for 6 months⁶. The longer a smoker stays abstinent, the better the chances that the abstinence will sustain. A

study measuring success rates found that only 12% of smokers who stopped smoking for one month remained abstinent at the follow up stage (i.e., 1.5 years). Of those who stayed abstinent for 1 – 3 months, 25% remained abstinent long term. A long term success rate of 52% could be found in smokers who stayed abstinent for 3 – 6 months, again suggesting that the longer the initial abstinence period, the greater the probability of long-term abstinence⁷. Therefore, due to these low abstinence rates it is necessary to find new pharmacotherapeutic options for nicotine addiction which could enhance abstinence rates.

The glutamate system and nicotine addiction

Glutamate is the major excitatory neurotransmitter in the central nervous system and is produced from glutamine by the enzyme glutaminase, which is localized in neurons and glia⁸. Over 90% of the synapses in the human brain are glutamatergic. Glutamate has the opposite effect to the neurotransmitter of Gamma Aminobutyric Acid (GABA), which is one of the main inhibitory neurotransmitters of the central nervous system. Numerous authors have suggested that glutamate signalling in the brain plays a major role in the nicotine addiction^{9,10,11}. Furthermore, glutamate neurotransmission in the CNS is involved in various disorders such as schizophrenia, depression, addiction, and neurodegenerative diseases, such as Alzheimer's, Parkinson's and multiple sclerosis^{11,12,13}. Glutamate signalling activates its receptors, which are categorized in two large groups: the metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors (iGluRs). Fast acting ionotropic (iGlu) receptors include N-methyl-D-aspartate receptor (NMDA), α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) and kainate. Slow acting metabotropic receptors involve the mGluR1-8. They are predominantly localized on postsynaptic as well as on glia cells in the brain, coupled with a G- protein. The mGlu receptors are classified into three

groups; Group I receptors (mGluR1 and mGluR5), Group II receptors (mGluR2 and mGluR3) and Group III receptors (mGluR4, mGluR6, mGluR7 and mGluR8) ⁸.

Several preclinical studies have found that nicotine increases glutamatergic transmission through activation of nicotinic acetylcholine receptor (nAChRs) located on glutamatergic afferents in the ventral tegmental area (VTA) and the nucleus accumbens (NAc) ¹⁴ (see Figure 1 for depiction of this action). Furthermore, long-term nicotine exposure could cause changes in dopamine and glutamate systems ⁸ For example, it was found that nicotine injections enhanced the brains reward function in rats as measured through intracranial self-administration ¹⁵. Nicotine dependence is the result of a positive effect of nicotine, specifically, it induces a dopamine (DA) increase in NAc. DA extracellular overflow is subsequently implicated in behavioural motivation and dependence, as it activates the reward system. Indeed, there is evidence that chronic nicotine administration can lead to a reduction of glutamate transmission in the meso-cortico-limbic system, mainly in NAc and VTA ^{8,16}. Early withdrawal symptoms in rats following chronic nicotine administration, was associated with decreased glutamate transmission and compensatory changes in glutamate receptors ¹⁶.

More recently, using Magnet Resonance Spectroscopy (MRS) in humans, the glutamatergic systems in nicotine addicted participants was investigated. The researchers found that smoking led to lower glutamate levels in the anterior cingulate cortex (ACC) and prefrontal cortex (PFC) ¹⁷ regions associated with reward processes. In another MRS study, glutamate levels in the thalamus were compared between smokers and non-smokers, showing lower thalamic glutamate in smokers ¹⁸.

Pharmacological interventions targeting the glutamate system have been used to discover novel therapeutic treatments for smokers. N- acetylcysteine is traditionally used as a mucolytic in chronic obstructive pulmonary disorder. It is a precursor of L-cysteine that has

Accepted Manuscript: Authors' Copy

105 the ability to enhance glutamate transmission and restore the reduced glutamate level caused
106 by nicotine addiction ^{19,20,21}. Studies have shown that treatment with N-acetylcysteine led to
107 participants reporting less withdrawal symptoms, decreasing their daily cigarette
108 consumption, and significantly decreasing the reward effect of nicotine consumption
109 compared to the control group ²². However, over time, about 50% of the participants relapsed
110 ^{20,23}.

111




Figure 1. The figure shows the processes leading to nicotine dependence. It shows that nicotine release, triggers an interaction with nAChRS on dopaminergic and glutamatergic neurons, particularly on mGlu5 receptor. Nicotine triggers the change of mGluR5 availability. It further illustrates the accumulating evidence suggesting that mGluR5 is significant in nicotine addiction.

The role of mGluR5 in nicotine addiction in preclinical studies

Metabotropic glutamate receptor 5 (mGluR5) belongs to the Group I metabotropic receptors and its actions are predominantly excitatory. Most mGluR5s are on postsynaptic neurons, but they are also found on presynaptic neurons, on glial cells, and on intracellular membranes with the ability to activate multiple cell signalling pathways. mGluR5 is a G protein-coupled receptor that activates phospholipase C, which produces diacyl glycerol and inositol triphosphate, which in turn increases calcium. Therefore, mGluR5 is responsible for Ca^{2+} fluctuations and regulates the activity of locomotor networks and neurotransmitter release. Recently, the extracellular signal-regulated kinase (ERK) as a downstream mediator of mGluR5 activity has been investigated in relation to addiction because of its role in synaptic plasticity, including maladaptive forms of plasticity associated with drug abuse²⁴. Furthermore, Calcium ions are one type of second messengers and the Ca^{2+} signalling pathway is a key component of the mechanisms that regulate neuronal excitability, information processing, and cognition, and it has been implicated in various neural diseases^{15,25,26}. A high density of mGluR5 can be found in several brain areas such as the forebrain, striatum, limbic system, amygdala, hippocampus, NAc, olfactory tubercle, and cerebral cortex²⁶. Furthermore, mGluR5 is critically implicated in normal and aberrant neuroplasticity and is involved in learning, motivation, motor coordination, reward behaviour, substance abuse, memory and emotion. Several recent reviews have suggested a potential association between

mGluR5 and nicotine addiction^{11,13,15}. In an mGluR5 knock out model study, it was suggested that this receptor is implicated in anhedonia and somatic signs of nicotine withdrawal²⁷. These findings are consistent with pharmacological studies showing mGluR5 related signalling in nicotine addiction. In animal studies, rats who were treated acutely with nicotine (subcutaneously) showed increased levels of extracellular glutamate in the NAc²⁸ and downregulation of mGluR5 expression^{8,14}. Such an inverse relationship between mGluR5 and glutamate levels as determined by MRS have also been found in humans²⁹. In addition, intracellular interactions between protein kinases and metabotropic receptors in the striatum, might regulate behavioural changes in response to drug abuse³⁰. Specifically, repeated exposure to nicotine increased ERK phosphorylation in adult rats³¹.

Interestingly, pharmacological studies have found functional interactions of mGluR5 with dopamine D1/D2, NMDA, adenosine A2, and GABA receptors^{11,13,15}. The mGlu5 receptor was co-localised with dopamine and adenosine receptors in the striatum, including the NAc, where they are involved in the regulation of dopaminergic neurotransmission^{15,25}.

More research is needed to understand the potential interactions between mGluR5 signalling and dopaminergic neurotransmission in the reward system. It is established that dopamine and glutamate system are anatomically closely located in the meso-cortico-limbic area. These brain regions are important in the regulation of motivation behaviours and emotions. Researchers have shown the interaction between mGlu5 and DA receptors, with mGluR5 being involved in the regulation of DA release in the NAc¹⁵. It can be suggested that mGluR5 plays a major role in the regulation of the reinforcing effects of nicotine through modulation of dopaminergic neurotransmission³². The interaction of both systems suggests the importance for both; controlling addiction, and reward related behaviour in nicotine addiction, by demonstrating that the strong rewarding effect of dopamine overflow can be modulated by mGluR5 inhibition¹⁵. Furthermore, the direct inhibition of NMDAR channels

are regulated by the mGlu5 receptors through the protein complex formed by Homer³³. Activation of NMDAR is responsible for long-term learning and memory and plays main role in development in drug addiction³⁴.

Therapeutical potential of mGluR5-NAMs in preclinical studies

Several studies used negative allosteric mGlu5 receptor antagonists MTEP (3-((2-Methyl-4-thiazolyl)ethynyl)pyridine) or MPEP (3-((2-Methyl-4-thiazolyl)ethynyl)pyridine)^{11,15} to study the relevance of mGluR5 signalling in nicotine addiction. Prior treatment with MPEP (which inhibits the responding for nicotine) for 30 minutes resulted in a dose-dependent reduction of nicotine self-administration while at the same time decreased extracellular DA level in NAc (Tronci & Balfour, 2011). Furthermore, pre-treatment with MPEP in rats inhibited responses to nicotine, suggesting MPEP inhibits nicotine seeking behaviour³⁵. Furthermore, the effect of MPEP administration in nicotine treated rats was highly significant compared to control, saline-treated rats. The response to nicotine in rats was greater if they were pre-treated with nicotine for eight days prior to the testing session³⁶. MPEP's effect on nicotine consumption may be mediated by intracellular protein kinases such as ERK in the brain reward system³¹. Mavoglurant and other medications (e.g. AZD2066, Basimglurant), which target mGluR5, have been examined in human research as an aid for nicotine cessation. However, these medications have the potential to cause some serious side effects in humans such as hallucinations, skin reactions and cognitive problems³⁶. MTEP and MPEP were shown to decrease nicotine intake, however, neither appeared to reduce the reward enhancing effects of nicotine. In an intravenous nicotine self-administration study, MPEP injection reduced self-administration in a dose dependent manner, while it did not alter general locomotion and lever pressing for sweetened food reward in rats³⁵. This could either indicate that food was a more rewarding treat than nicotine or a nicotine specific

involvement of mGluR5. mGluR-NAMs lead to a reduction of nicotine self-administration but have no influence on the motivation enhancing effect of nicotine^{36,37}. In a wide preclinical study, rats that received the pre-treatment with MPEP and were either non-conditioned or operant conditioned to nicotine, showed that MPEP attenuated the reinforcing properties of nicotine. It suggests that the activity of mGlu5 receptors may play an important role in provoking drug-seeking behaviour and nicotine cravings in habitual smokers exposed to cues associated with their smoking habit³⁵. In addition, pre-treating rats with dose dependent MPEP, nicotine causes attenuated DA overflow in the NAc^{15,35}. It is therefore hypothesised that mGluR5 antagonists downregulate the increasing extracellular DA from injections of nicotine. Antagonists at mGlu5 receptors may therefore lead to smoking cessation^{14,15,35}. But a further study with rats showed that MPEP enhances the effect of nicotine and induces the conditioned place preference (CPP)³⁸. It was hypothesised that the effect of MPEP on the mesolimbic system may induce the rewarding effect of nicotine³⁸. However, this finding differs from past studies^{14,15,35,39}. In addition, mGluR5-targeting drugs may help to prevent relapse during nicotine withdrawal. The mGluR5 NAM showed a significant potential therapeutic effect, decreasing nicotine seeking behaviour^{11,15,36}. Furthermore, mGluR5 NAM should not lead to altering mood or cognitive enhancing effects of nicotine³⁷. Similarly, preclinical studies on the effects of mGluR5 NAMs during early nicotine abstinence have shown that these drugs may worsen the somatic and depression-like symptoms of nicotine withdrawal^{15,36}. The situation of either timing or combination of mGluR5 targeting therapeutics needs further investigation.

mGluR5 and nicotine addiction in humans

Positron Emission Tomography (PET) radioligands like [11C]ABP688⁴⁰ are used in humans to assess the distribution of mGluR5 in the brain and its subsequent role in smoking addiction.

In a series of studies, the availability of mGluR5 in non-smokers, smokers and ex-smokers (abstinent for an average of 25 weeks) was investigated ^{9,10}. These results provided support for markedly lower mGluR5 density in smokers. Amongst 14 smokers, global mGluR5 distribution volume ratio (DVR) was 20.6% lower in the gray matter compared to 14 non-smokers ⁹. Furthermore, it was found that 14 ex-smokers, had a higher mGluR5 density compared to smokers, which may be due to incomplete recovery of the receptors, especially because the ex-smokers were abstinent for only 25 weeks on average. Lower mGluR5 binding may be an adaptation to chronic increases in glutamate as a result of chronic nicotine administration (See Figure 2). In a follow-up study, 14 non-smokers, 14 smokers, 14 long-term ex-smokers (abstinent for greater than 1.5 years), and 14 recent ex-smokers (abstinent for 5-12 month) were compared. Long-term ex-smokers and non-smokers showed no difference in mGluR5 binding and long-term ex-smokers showed significantly higher mGluR5 binding compared to recent ex-smokers. Seven of the recent ex-smokers were still abstinent even after one year and showed higher mGluR5 distribution volumes at baseline than relapsing participants ¹⁰. The effect of smoking on mGluR5 availability is strong ^{9,10} and comparable to nicotine effects on mGluR5 in cocaine users ⁴¹. Here, smoking results in lower mGluR5 binding than in the cocaine using and control groups, and cocaine does not appear to affect mGluR5 binding ⁴¹. A similar reduction of mGluR5 binding as a result of smoking has also been shown in schizophrenia ⁴². It is suggested, that chronic nicotine abuse disturbed the homeostasis of glutamatergic transmission, and might lead - via increasing glutamate release - to a down regulation of mGluR5 density in the cortex ^{9,15}.




Figure 2. Images display the average brain uptake of mGluR5 DVR in the three diagnostic groups. The brain uptake is visibly reduced in the smoker and ex-smoker group, compare with the non-smoker group (See ⁹ open access.).

A current longitudinal animal study has shown the impact of chronic nicotine exposure on mGluR5 using the novel radiotracer [18F]PSS232. Here, PET shows lower [18F]PSS232 binding. Furthermore, after prolonged nicotine withdrawal, [18F]PSS232 binding normalized in these rodents ⁴³. These results replicate those from a previous study by the authors ⁹. However, a further study on mGluR5 binding in Major Depressive Disorder found significantly lower caudate mGluR5 DVR in smokers relative to non-smokers, although this difference did not survive correction for multiple comparisons ²⁹.

In summary, there is growing preclinical and clinical evidence that mGluR5 plays an important role in nicotine addiction. So far, drugs targeting mGluR5 did not show clinical utility because of lack of consistent efficacy or severe side effects. Nevertheless, findings

250 encourage research into therapeutic drugs targeting mGluR5 as combination therapies for
251 patients to treat their nicotine addiction.

252 References

- 253
- 254 1. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. *Lancet*
- 255 *Psychiatry*. 2016;3(8):760-773. doi: 10.1016/S2215-0366(16)00104-8.
- 256 2. WHO. Tobacco 2018; <http://www.who.int/en/news-room/fact-sheets/detail/tobacco>.
- 257 3. Collins GB, Jerry JM, Bales R. Quitting smoking: still a challenge, but newer tools show
- 258 promise. *Cleve Clin J Med*. 2015;82(1):39-48. doi: 10.3949/ccjm.81a.14016.
- 259 4. D'Souza MS. Neuroscience of nicotine for addiction medicine: novel targets for smoking
- 260 cessation medications. *Prog Brain Res*. 2016; 223:191-214. doi:
- 261 10.1016/bs.pbr.2015.07.008.
- 262 5. Malarcher A. 2011; <https://www.cdc.gov/mmwr/index.html>.
- 263 6. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among
- 264 untreated smokers. *Addiction*. 2014;99(1):29-38.
- 265 7. Gilpin EA, Pierce JP, Farkas AJ. Duration of smoking abstinence and success in quitting. *J*
- 266 *Natl Cancer Inst*. 1997;89(8):572-576.
- 267 8. Pistillo F, Clementi F, Zoli M, Gotti C. Nicotinic, glutamatergic and dopaminergic synaptic
- 268 transmission and plasticity in the mesocorticolimbic system: focus on nicotine effects. *Prog*
- 269 *Neurobiol*. 2015;124:1-27. doi: 10.1016/j.pneurobio.2014.10.002.
- 270 9. Akkus F, Ametamey SM, Treyer V, Burger C, Johayem V, Umbricht D, et al. Marked
- 271 global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by
- 272 [11C]ABP688 positron emission tomography. *Proc Natl Acad Sci U S A*. 2013;110(2):737-
- 273 742. doi: 10.1073/pnas.1210984110
- 274 10. Akkus F, Treyer V, Johayem A, Ametamey SM, Mancilla BG, Sovago J, et al. Association
- 275 of Long-Term Nicotine Abstinence With Normal Metabotropic Glutamate Receptor-5
- 276 Binding. *Biol Psychiatry*. 2016;79(6):474-480. doi: 10.1016/j.biopsych.2015.02.027.
- 277 11. Mihov Y, Hasler G. Negative Allosteric Modulators of Metabotropic Glutamate Receptors
- 278 Subtype 5 in Addiction: a Therapeutic Window. *Int J Neuropsychopharmacol*.
- 279 2016;19(7):1-11. doi: 10.1093/ijnp/pyw002.
- 280 12. Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling
- 281 pathways. *Int J Biol Sci*. 2013;9(9):948-959. doi: 10.7150/ijbs.6426.
- 282 13. Terbeck S, Akkus F, Chesterman LP, Hasler G. The role of metabotropic glutamate receptor
- 283 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with
- 284 human Positron Emission Tomography (PET) studies. *Front Neurosci*. 2015;9(86). doi:
- 285 10.3389/fnins.2015.00086.
- 286 14. Li X, Semenova S, D'Souza MS, Stoker AK, Markou A. Involvement of glutamatergic and
- 287 GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for
- 288 smoking cessation. *Neuropharmacology*. 2014;76 Pt B:554-565. doi:
- 289 10.1016/j.neuropharm.2013.05.042.
- 290 15. Chiamulera C, Marzo CM, Balfour DJK. Metabotropic glutamate receptor 5 as a potential
- 291 target for smoking cessation. *Psychopharmacology (Berl)*. 2017;234(9-10):1357-1370. doi:
- 292 10.1007/s00213-016-4487-3.
- 293 16. D'Souza MS, Markou A. Neuronal mechanisms underlying development of nicotine
- 294 dependence: implications for novel smoking-cessation treatments. *Addict Sci Clin Pract*.
- 295 2011;6(1):4-16.

- 296 17. Moeller SJ, London ED, Northoff G. Neuroimaging markers of glutamatergic and
297 GABAergic systems in drug addiction: Relationships to resting-state functional connectivity.
298 *Neurosci Biobehav Rev.* 2016;61:35-52. doi: 10.1016/j.neubiorev.2015.11.010.
- 299 18. O'Neill J, Tobias MC, Hudkins M, Oh EY, Hellemann GS, Nurmi EL, et al. Thalamic
300 glutamate decreases with cigarette smoking. *Psychopharmacology (Berl)*.
301 2014;231(13):2717-2724. doi: 10.1007/s00213-014-3441-5.
- 302 19. Asevedo E, Mendes AC, Berk M, Brietzke E. Systematic review of N-acetylcysteine in the
303 treatment of addictions. *Rev Bras Psiquiatr.* 2014;36(2):168-175.
- 304 20. McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-
305 acetylcysteine in the management of substance use disorders. *CNS Drugs.* 2014;28(2):95-
306 106. doi: 10.1007/s40263-014-0142-x.
- 307 21. Bowers MS, Jackson A, Maldoon PP, Damaj MI. N-acetylcysteine decreased nicotine
308 reward-like properties and withdrawal in mice. *Psychopharmacology (Berl)*.
309 2016;233(6):995-1003. doi: 10.1007/s00213-015-4179-4.
- 310 22. Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-
311 acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled
312 pilot study. *Eur Addict Res.* 2011;17(4):211-216. doi: 10.1159/000327682.
- 313 23. Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, et al. Clinical trials of N-
314 acetylcysteine in psychiatry and neurology: A systematic review. *Neurosci Biobehav Rev.*
315 2015;55:294-321. doi: 10.1016/j.neubiorev.2015.04.015
- 316 24. Stevenson RA, Hoffman JL, Maldonado-Devincci AM, Faccidomo S, Hodge CW. mGluR5
317 activity is required for the induction of ethanol behavioural sensitization and associated
318 changes in ERK MAP kinase phosphorylation in the nucleus accumbens shell and lateral
319 habenula. *Behavioural Brain Research.* 2019;23:19-27, doi: [10.1016/j.bbr.2019.03.038](https://doi.org/10.1016/j.bbr.2019.03.038)
- 320 25. Jong YJ, Sergin I, Purgert CA, O'Malley KL. Location-dependent signaling of the group 1
321 metabotropic glutamate receptor mGlu5. *Mol Pharmacol.* 2014;86(6):774-785. doi:
322 10.1124/mol.114.094763.
- 323 26. Olmo IG, Ferreira-Vieira TH, Ribeiro FM. Dissecting the Signaling Pathways Involved in
324 the Crosstalk between Metabotropic Glutamate 5 and Cannabinoid Type 1 Receptors. *Mol*
325 *Pharmacol.* 2016;90(5):609-619. doi: 10.1124/mol.116.104372.
- 326 27. Stoker AK, Olivier B, Markou A. Involvement of metabotropic glutamate receptor 5 in brain
327 reward deficits associated with cocaine and nicotine withdrawal and somatic signs of
328 nicotine withdrawal. *Psychopharmacology (Berl)*. 2012;221(2):317-327. doi:
329 10.1007/s00213-011-2578-8.
- 330 28. Reid MS, Fox L, Ho LB, Berger SP. Nicotine stimulation of extracellular glutamate levels in
331 the nucleus accumbens: neuropharmacological characterization. *Synapse.* 2000;35(2):129-
332 136. doi: 10.1002/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0.CO;2-D.
- 333 29. Abdallah CG, Hannestad J, Mason GF, Holmes SE, DellaGioia N et al. Metabotropic
334 Glutamate Receptor 5 and Glutamate involvement in Major Depressive Disorder: A
335 multimodal imaging study. *Biological Psychiatry: Cognitive Neuroscience and*
336 *Neuroimaging.* 2017;2(5):449-456, doi: [10.1016/j.bpsc.2017.03.019](https://doi.org/10.1016/j.bpsc.2017.03.019)
- 337 30. Lee AM, Messing RO. Protein Kinases and Addiction. *Annals of the New York Academy of*
338 *Sciences.* 2011;1141:22-57, doi: [10.1196/annals.1441.022](https://doi.org/10.1196/annals.1441.022)
- 339 31. Yang JH, Sohn S, Kim S, Kim J, Oh JH, Ryu I S, Go BS, Choe ES. Repeated nicotine
340 exposure increases the intracellular interaction between ERK-mGluR5 in the nucleus
341 accumbens more in adult than adolescent rats. *Addiction Biology.* 2020. doi:
342 [10.1111/adb.12913](https://doi.org/10.1111/adb.12913)
- 343

- 344 32. Paterson NE, Semenova S, Gasparini F, Markou A. The mGluR5 antagonist MPEP
345 decreased nicotine self-administration in rats and mice. *Psychopharmacology (Berl)*.
346 2003;167(3):257-264. doi: 10.1007/s00213-003-1432-z.
- 347 33. Moutin E, Raynaud F, Roger J, Pellegrino E, Homburger V, Bertaso F, et al. Dynamic
348 remodeling of scaffold interactions in dendritic spines controls synaptic excitability. *J Cell*
349 *Biol*. 2012;198(2):251-263. doi: 10.1083/jcb.201110101
- 350 34. Andrzejewski M, McKee B, Baldwin A, Burns L, Hernandez P. The clinical relevance of
351 neuroplasticity in corticostriatal networks during operant learning. *Neuroscience &*
352 *Biobehavioral Reviews*. 2013;37(9):2071-2080. doi: 10.1016/j.neubiorev.2013.03.019
- 353 35. Tronci V, Vronskaya S, Montgomery N, Mura D, Balfour DJ. The effects of the mGluR5
354 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses
355 to nicotine. *Psychopharmacology (Berl)*. 2010;211(1):33-42. doi: 10.1007/s00213-010-
356 1868-x.
- 357 36. Barnes S, Sheffler D, Semenova S, Cosford N, Bernalov A. Metabotropic Glutamate
358 Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical
359 Data but Inconclusive Clinical Efficacy. *Biological Psychiatry*. 2018;83(11):955-962. doi:
360 10.1016/j.biopsych.2018.03.001
- 361 37. Palmatier M, Liu X, Donny E, Caggiula A, Sved A. Metabotropic Glutamate 5 Receptor
362 (mGluR5) Antagonists Decrease Nicotine Seeking, But Do Not Affect the Reinforcement
363 Enhancing Effects of Nicotine. *Neuropsychopharmacology*. 2007;33(9):2139-2147. doi:
364 10.1038/sj.npp.1301623
- 365 38. Rutten K, Van Der Kam E, De Vry J, Bruckmann W, Tzschentke T. The mGluR5 antagonist
366 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference
367 induced by various addictive and non-addictive drugs in rats. *Addiction*
368 *Biology*. 2010;16(1):108-115. doi: 10.1111/j.1369-1600.2010.00235.x
- 369 39. Tronci V, Balfour DJ. The effects of the mGluR5 receptor antagonist 6-methyl-2-
370 (phenylethynyl)-pyridine (MPEP) on the stimulation of dopamine release evoked by
371 nicotine in the rat brain. *Behav Brain Res*. 2011;219(2):354-357. doi:
372 10.1016/j.bbr.2010.12.024.
- 373 40. Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, et al. Human PET
374 studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. *J Nucl Med*.
375 2007;48(2):247-252.
- 376 41. Hulka LM, Treyer V, Scheidegger M, Preller KH, Vonmoos M, Baumgartner MR, et al.
377 Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate
378 receptor 5 density in humans. *Mol Psychiatry*. 2014;19(5):625-632. doi:
379 10.1038/mp.2013.51.
- 380 42. Akkus F, Treyer V, Ametamey SM, Johayem A, Buck A, Hasler G. Metabotropic glutamate
381 receptor 5 neuroimaging in schizophrenia. *Schizophr Res*. 2017;183:95-101. doi:
382 10.1016/j.schres.2016.11.008.
- 383 43. Müller Herde A, Mihov Y, Kramer SD, Mu L, Adamantidis A, Ametamey SM, Hasler G.
384 Chronic nicotine exposure alters metabotropic glutamate receptor 5: Longitudinal PET study
385 and behavioural assessment in rats. *Neurotoxicity Research*. 2019;36:808-816,
386 <https://doi.org/10.1007/s12640-019-00055-5>
387